Izalontamab SI-B001: An Promising New Immunoglobulin Therapy
Izalontamab SI-B001 is a significant step forward in hematologic treatment of refractory multiple myeloma. The innovative antibody directly binds to BCMA on myeloma cells, leading to antibody-dependent cellular cytotoxicity or eliciting anti-tumor immune responses. Initial investigational evidenc